STOCK TITAN

Adial Pharmaceuticals Inc - ADIL STOCK NEWS

Welcome to our dedicated news page for Adial Pharmaceuticals (Ticker: ADIL), a resource for investors and traders seeking the latest updates and insights on Adial Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Adial Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Adial Pharmaceuticals's position in the market.

Rhea-AI Summary
Adial Pharmaceuticals regains compliance with Nasdaq listing rules
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.34%
Tags
none
-
Rhea-AI Summary
Adial Pharmaceuticals reports positive feedback from regulatory meetings and significant reduction in cash burn rate
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.76%
Tags
-
Rhea-AI Summary
Adial Pharmaceuticals announces a 1-for-25 reverse stock split of its common stock, effective August 4, 2023. The split will reduce outstanding shares from 30.5 million to 1.2 million. The reverse split aims to bring the company into compliance with Nasdaq's minimum bid price requirement and attract a broader group of investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4%
Tags
none
Rhea-AI Summary
Adial Pharmaceuticals provides an update on its clinical development plan for AD04, a treatment for Alcohol Use Disorder. The company received positive feedback from regulators and plans to focus on the US market. They will conduct two Phase 3 trials to support potential approval, with a total cost of approximately $25 million. AD04 is expected to be registered with the FDA in Q3 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
95%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
conferences
-
Rhea-AI Summary
Adial Pharmaceuticals provides business update and financial results for Q1 2023. The company conducted meetings with regulatory agencies and received upfront cash from the sale of Purnovate assets. They also engaged The Keswick Group for partnering efforts. Adial closed a registered direct offering and ended Q1 with $2.3 million in cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.25%
Tags
Rhea-AI Summary
Adial Pharmaceuticals announced that Adovate has exercised its option to acquire the assets and business of Purnovate. Adial will receive an upfront payment of $450,000 and expense reimbursement of approximately $0.9 million. They are also entitled to receive up to $83 million in milestone payments and a 19.9% equity stake in Adovate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.64%
Tags
conferences
Adial Pharmaceuticals Inc

Nasdaq:ADIL

ADIL Rankings

ADIL Stock Data

9.08M
3.94M
4.02%
6.53%
0.52%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Charlottesville

About ADIL

adial pharmaceuticals is dedicated to personalized treatment for drug abuse and addiction. while our pipeline includes drug candidates for the treatment of opiate and amphetamine use, our two lead drug candidates are for the treatment of alcohol abuse. adial leverages its extensive knowledge of pharmacology and pharmacogenomics to change the paradigm of drug abuse treatment.